A Phase I, Dose Finding Study of the Combination of High-dose Statin Agent (Rosuvastatin) With Erlotinib in Patients With Advanced Solid Malignancies, With a Focus on Squamous Cell Carcinomas and NSCLC.

Trial Profile

A Phase I, Dose Finding Study of the Combination of High-dose Statin Agent (Rosuvastatin) With Erlotinib in Patients With Advanced Solid Malignancies, With a Focus on Squamous Cell Carcinomas and NSCLC.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 May 2017

At a glance

  • Drugs Rosuvastatin (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 18 Feb 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015, as per ClinicalTrials.gov record.
    • 13 Jan 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top